Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Avidity Biosciences Inc (NASDAQ: RNA) closed at $43.95 down -7.08% from its previous closing price of $47.30. In other words, the price has decreased by -$7.08 from its previous closing price. On the day, 0.95 million shares were traded. RNA stock price reached its highest trading level at $47.06 during the session, while it also had its lowest trading level at $43.94.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.78 and its Current Ratio is at 15.78. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on September 24, 2024, initiated with a Buy rating and assigned the stock a target price of $59.
On August 28, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $63.
On May 03, 2024, BofA Securities started tracking the stock assigning a Buy rating and target price of $40.BofA Securities initiated its Buy rating on May 03, 2024, with a $40 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 07 ’24 when Thompson Tamar bought 30,000 shares for $47.30 per share.
Flanagan W. Michael sold 62,500 shares of RNA for $2,976,112 on Oct 01 ’24. The CSTO now owns 85,389 shares after completing the transaction at $47.62 per share. On Oct 01 ’24, another insider, WILLIAM MICHAEL FLANAGAN, who serves as the Officer of the company, bought 38,018 shares for $45.93 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 5587978752 and an Enterprise Value of 3535107328. For the stock, the TTM Price-to-Sale (P/S) ratio is 485.61 while its Price-to-Book (P/B) ratio in mrq is 3.93. Its current Enterprise Value per Revenue stands at 333.532 whereas that against EBITDA is -12.506.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $49.41, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 0.28%, while the 200-Day Moving Average is calculated to be 51.45%.
Shares Statistics:
For the past three months, RNA has traded an average of 1.44M shares per day and 1557560 over the past ten days. A total of 117.12M shares are outstanding, with a floating share count of 108.62M. Insiders hold about 7.26% of the company’s shares, while institutions hold 93.21% stake in the company. Shares short for RNA as of 1726185600 were 11979442 with a Short Ratio of 8.31, compared to 1723680000 on 12918389. Therefore, it implies a Short% of Shares Outstanding of 11979442 and a Short% of Float of 12.520000000000001.
